Home > Products > Antibodies > Biosimilars

Anti-Human CFD Reference Antibody (Lampalizumab, RUO) (HF697016)

Datasheet Share product Copy info

Anti-Human CFD Reference Antibody (Lampalizumab, RUO)

Anti-Human CFD Reference Antibody (Lampalizumab, RUO)

Price(USD): $

Spec:

100ug
1mg

Number:

Contact us

Overview
Images
References
Datasheet
SDS

Overview

Catalog No.	HF697016
Description	Lampalizumab (HF697016) is a research-grade recombinant antibody targeting PFD. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Species reactivity	Human
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host species	Humanized
Isotype	Fab-G1-kappa
Expression system	Mammalian Cells
Clonality	Monoclonal
Target	PFD, Adipsin, C3 convertase activator, Complement factor D, CFD, DF, Properdin factor D
Endotoxin level	Please contact the lab for this information.
Purity	>95% purity as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Accession	P00746
Form	Liquid
Storage buffer	0.01M PBS, pH 7.4. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Alternate Names	AFD, Anti-fD, Anti-FACTORD, FCFD4514S, RG7417, 1278466-20-8
Background	Complement factor D (CFD) is a ~27 kDa protein. Serine protease that initiates the alternative pathway of the complement system, a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system. In contrast to other complement pathways (classical, lectin and GZMK) that are directly activated by pathogens or antigen-antibody complexes, the alternative complement pathway is initiated by the spontaneous hydrolysis of complement C3. The alternative complement pathway acts as an amplification loop that enhances complement activation by mediating the formation of C3 and C5 convertases. Activated CFD cleaves factor B (CFB) when the latter is complexed with complement C3b, activating the C3 convertase of the alternative pathway. 1. Forneris, F. et al. (2010) Science (New York, N.Y.) 330, 1816-20. PMID: 21205667 2. Katschke, KJ. et al. (2012) The Journal of biological chemistry 287, 12886-92. PMID: 22362762 3. Niemann, MA. et al. (1980) Biochemistry 19, 1576-83. PMID: 6769474 4. Volanakis, JE. et al. (1977) Journal of immunology (Baltimore, Md. : 1950) 119, 337-42. PMID: 874324 5. Hourcade, DE. et al. (1998) The Journal of biological chemistry 273, 25996-6000. PMID: 9748277
Note	For research use only. Not suitable for clinical or therapeutic use.

Images

Bioactivity

Detects CFD in indirect ELISAs.

References

Datasheet

Anti-Human CFD Reference Antibody (Lampalizumab, RUO).pdf

Download SDS PDF

Formula

Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)

Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.

Mass

=

Concentration

×

Volume

Molecular Weight *

g/mol

Formula

C₁ × V₁ = C₂ × V₂

Enter any 3 of the 4 values to solve for the unknown.

Stock Solution

C₁ (Stock Conc.)

×

V₁ (Stock Vol.)

=

Working Solution

C₂ (Working Conc.)

×

V₂ (Working Vol.)

Recommendation

Contact us for custom quotes, bulk requests and any other issues.

Mail: support@abinScience.com

Distributor list

Anti-Human CFD Reference Antibody (Lampalizumab, RUO)